Altoida Secures Funding and Research Partnership with Eisai Innovation

Altoida announced new financing from Eisai Innovation, Inc. In addition, the start-up will work together with the Eisai Innovation team. “Eisai’s deep expertise and global leadership in dementia-related diseases and neurodegenerative diseases makes them a perfect partner to accelerate Altoida’s ability to develop and deliver high-accuracy predictive brain health diagnostics in a non-invasive, cost-effective, and scalable way” said Travis Bond, CEO of Altoida, Inc.

Leveraging the experience gained from the development and marketing of a treatment for Alzheimer’s disease, Eisai aims to establish the “Eisai Dementia Platform.” Through this platform, Eisai plans to deliver novel benefits to those living with dementia and their families through constructing a “Dementia Ecosystem,” by collaborating with partners. Eisai Co., Ltd. is a leading global pharmaceutical company headquartered in Japan. With more than 10,000 employees, the company delivers innovative products in various therapeutic areas with a focus on Neurology and Oncology.

“For three decades, Eisai has delivered hope through innovation by bringing life-changing insights and therapies,” said Kazumasa Nagayama, Chief Strategy Officer (CSO) of Eisai Co., Ltd. “The work Altoida is doing with digital biomarkers may prove to revolutionize how we approach dementias, including Alzheimer’s disease, allowing interventions years ahead of traditional methods.”

Rather than complete a memory test or similar questionnaire, Altoida’s users complete a 10 minute set of digital and augmented reality activities on their smartphone or tablet. While the activities feel like a game, they immerse the brain to assess it in its most realistic, ecologically valid state. From these activities, Altoida collects data from the sensors in the users’ device to analyze over 780 proprietary digital biomarkers and provide an objective measurement of brain function across 11 unique cognitive domains.

With these personalized brain measurements, Altoida is working to use artificial intelligence to predict an individual’s risk of conversion from Mild Cognitive Impairment (MCI) to Alzhimer’s disease, years in advance of symptoms. This should enable preventative and therapeutic intervention to help delay disease onset and improve patient management and outcomes.

(Press release / SK)